Eli Lilly Reports Promising Data for Alopecia and Eczema Drugs, Eyes Label Expansion - Regional Media News

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often...

Baricitinib demonstrates sustained hair regrowth in adolescents with alopecia areata

New one-year data showed that baricitinib continued scalp, eyebrow, and eyelash regrowth in adolescents with severe alopecia areata.

Lilly and Incyte to seek approval of alopecia JAK inhibitor in children

Lilly and Inctye will be seeking a label update for the JAK inhibitor for its use in paediatric patients with alopecia areata.The post Lilly and Incyte to seek approval of alopecia JAK inhibitor in children appeared first on Clinical Trials Arena.

Eli Lilly to seek Olumiant approval in adolescents with alopecia

Eli Lilly said Friday it plans to ask the FDA for a label expansion of its immunology drug Olumiant in adolescents with alopecia after successful long-term data. At one year of follow-up, Lilly said 54 ...

Eli Lilly reports promising data for alopecia and eczema drugs, eyes label expansion - Regional Media News

(Reuters) -Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for alopecia and eczema. The company was testing baricitinib, sold under the brand name Olumiant, in 257 adolescent patients with severe alopecia areata or patchy hair loss. In the trial, a 4 milligram dose of baricitinib helped improve hair regrowth in more than 50% of adolescents after one year of treatment. Succ…